Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Endocrinology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) in renal proximal tubules reabsorbs 90% of glucose.
• SGLT2 inhibition offers a therapeutic strategy for T2DM by promoting urinary glucose excretion.
• Selective SGLT2 inhibitors minimize side effects like gastrointestinal issues and hypoglycemia.

Purpose of the Study:

• To review and classify C-aryl glucoside SGLT2 inhibitors based on structural features.
• To discuss structure-activity relationships (SARs) of these inhibitors.
• To analyze their inhibitory potency against human SGLT2 and selectivity over SGLT1.

Main Methods:

• Classification of SGLT2 inhibitors into three types: phenyl/arylmethylphenyl C-glucosides, heteroarylmethylphenyl C-glucosides, and glucose-modified C-aryl glucosides.
• Emphasis on structural modifications of the phenyl rings and spacers.
• Analysis of SARs, inhibitory potency, and selectivity data.

Main Results:

• Detailed categorization of C-aryl glucoside SGLT2 inhibitors based on core structures and modifications.
• Insights into how structural variations influence SGLT2 inhibitory activity and SGLT1 selectivity.
• Identification of key structural elements for developing potent and selective SGLT2 inhibitors.

Conclusions:

• C-aryl glucosides represent a stable and effective class of SGLT2 inhibitors for T2DM treatment.
• Structural classification and SAR analysis are vital for optimizing inhibitor design.
• Ongoing research focuses on developing novel SGLT2 inhibitors with improved efficacy and safety profiles.